Matthew Oberley: Using GPSai to Guide Cancer of Unknown or Misclassified Primary Diagnosis

Matthew Oberley, Chief Clinical Officer at Caris Life Sciences, shared a post on LinkedIn:

“Join Theodore Nicolaides, MD and me to discuss the clinical utility of our whole exome and whole transcriptome sequencing algorithm GPSai coupled with other clinically validated molecular outputs from our MI Cancer Seek tissue profiling test, including COSMIC UV and Tobacco signatures, fusions, viruses (MCV, HPV, EBV, HHV8), and RNA expression data to achieve diagnostic certainty.

All from one molecular profiling test with minimal tissue requirements.

Caris Educational Webinar.”

More posts featuring Matthew Oberley on OncoDaily.